Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-05-30

Clinical Trial Update: Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for eculizumab in paroxysmal nocturnal hemoglobinuria shows the study status as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SOLIRIS (eculizumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Leukemia | Phase 3 | Status: COMPLETED